I am very excited about my new opportunity at Medelis. This is a company that has developed a solid reputation as an oncology focused CRO.
Nashville, TN (PRWEB) May 28, 2015
Medelis, Inc., a specialty oncology CRO, today announced that Bill Taaffe has joined the company in the role of president.
“Bill Taaffe has a proven track record of leadership in the CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He will be a great addition to guide the company through our next phase of growth.”
Taaffe joined ICON’s U.S. clinical operations in 1993 and oversaw its growth from nine employees to over 4,500 employees, achieving 12 consecutive years of growth and regional expansion. Taaffe also served as ICON’s president of corporate development and president of DOCS, ICON’s staffing division.
"I am very excited about my new opportunity at Medelis. This is a company that has developed a solid reputation as an oncology focused CRO,” said Taaffe. “I spent 18 wonderful years at ICON Clinical Research where the focus is on patients, quality and people. This enabled ICON to grow into one of the most successful CROs in the world. At Medelis I see the same focus and I am confident we will experience similar success."
Taaffe was recognized as one of the industry’s 100 most inspiring people by PharmaVoice in 2011. He received a B.S., University College of Dublin and lives in Nashville, Tennessee.
Medelis is a specialty oncology CRO focused on phase I through phase III oncology trials in North America and Europe. Founded in 2003, Medelis provides sponsors with oncology expertise from drug development thought-leadership to a highly skilled clinical operations team, handling complex oncology trials in all indications including cutting-edge immunotherapy treatments.